India Bans All Exports of Virus Drug Often Touted by Trump
(Bloomberg) --
India banned all exports of hydroxychloroquine, a malaria drug that President Donald Trump has repeatedly touted as a “game changer” in the fight against Covid-19.
Exports of the drug and its formulations are prohibited “without any exceptions” and with immediate effect, India's Directorate General of Foreign Trade said in an April 4 order on its website. The trade regulator had last month restricted overseas shipments of the drug, allowing only limited exceptions such as on humanitarian grounds and for meeting prior commitments.
At a press conference on Saturday, Trump said he spoke to Indian Prime Minister Narendra Modi and appealed for the release of shipments U.S. has already ordered. India is giving his request “serious consideration,” he said.
On Sunday, Trump continued to promote the drug, saying the U.S. has secured 29 million choloroquine or hydroxychloroquine pills for its medical stockpile, again touting the drug's promise despite an absence of scientific scrutiny. Saying he was “trying to save lives,” the president asked “what really do we have to lose?”
“I've seen things I sort of like,” Trump said at a White House news conference. “What do I know, I'm not a doctor. But I have common sense.”
U.S. Surgeon General Jerome Adams on Sunday said there had been “some accounts, some stories” about hydroxychloroquine “helping” and the drug has been available for years.
“We feel a little bit better regarding its safety than we do about a completely novel drug, even though this is being used at much higher dosages,” Adams said on “Fox News Sunday”
There's no conclusive scientific evidence that hydroxychloroquine can treat the infection from the novel pathogen, and it hasn't been approved by the Food and Drug Administration in the U.S. to treat Covid-19.
Trump has been undeterred, though. “What do you have to lose? Take it,” the president said at Saturday's briefing. “I really think they should take it. But it's their choice.”
“We just want to be able to facilitate physicians and patients having that conversation,” Adams said. “That's what I tell people. That's what I've heard the president tell people.”
The ban reflects India's rising concern over the rapid spread of the coronavirus, with risks of community spread rising in the country of 1.3 billion people.
India has recorded 3,374 positive cases so far and has lost 77 lives, according to the federal health ministry. The country has struggled to keep people indoors during a three-week lockdown that started March 25, raising fears of accelerating spread.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.